Chonluten

Chonluten is a synthetic tripeptide, a chain of just three amino acids, with the sequence Glu-Asp-Gly, usually shortened to EDG ¹. It belongs to the Khavinson family of short peptide bioregulators, tissue-derived peptides that Russian researchers began characterizing in 1973 and that are selected for activity in specific organs ¹. Chonluten is the bronchial member of the family, originally derived from bronchial epithelial cells, the cells that line the airways ¹. Do not confuse similarly named Khavinson short peptides: Pinealon is Glu-Asp-Arg (EDR), Livagen is Lys-Glu-Asp-Ala, and Bronchogen is a separate bronchial-line peptide product. Verify the printed sequence, not the brand name, before ordering.

The same three-amino-acid motif, Glu-Asp-Gly (EDG), appears at the core of a larger immunoregulatory peptide called thymic humoral factor gamma-2 (THF-γ2), where it occupies positions 2 through 4 ². Chonluten's own sequence is Glu-Asp-Gly (EDG), not Glu-Asp-Arg (EDR), so findings reported specifically for the EDR peptide (Pinealon) should not be attributed to Chonluten. EDG-containing peptides such as Epitalon, THF-γ2, and testagen share Chonluten's core motif, but each is a different molecule and their results still require direct demonstration for Chonluten. Across the available studies, Chonluten's EDG sequence shows a damping effect on inflammatory signaling in human immune cells ¹. The separate tripeptide Glu-Asp-Arg (EDR, Pinealon) reduced oxidative DNA damage and improved neuron-branch growth in aged human neurons grown in culture ⁵, but that neuronal signature belongs to EDR, not to Chonluten.

Indications studied, with confidence levels:

• Chronic bronchial and lung inflammation (bronchitis, asthma/COPD adjunct): moderate confidence, based on cell-line data and long-standing community use
• Post-infectious respiratory recovery: low to moderate confidence
• Broad anti-inflammatory immunomodulation: moderate confidence on mechanism, from a human monocyte/macrophage cell line ¹
• Age-related immune decline: low confidence, family-level data only

The evidence base is all laboratory work at this stage. The strongest dataset is a 2022 study in a human monocyte and macrophage cell line ¹, and no human clinical trial has yet been published for Chonluten.

Chonluten's best-documented effect is a readjustment of the innate immune response. In human monocyte and macrophage cultures, the first-responder cells of the immune system, exposure to Chonluten leaves cells releasing far less of two key inflammatory signals, TNF and IL-6, when they are later challenged with bacterial endotoxin (lipopolysaccharide, or LPS) ¹. The pattern matches a known cellular program called TNF tolerance, in which the inflammatory response is turned down rather than switched off. The cells still recognize the bacteria; they simply respond less aggressively ¹. The specific receptor or sensor that recognizes Chonluten has not been identified ¹.

The damped response also extends to cell movement. Peptide-treated immune cells adhere less to activated blood-vessel walls (endothelium), the earliest step in inflammatory cells leaving the bloodstream and entering tissue ¹. The peptide also increases the activity (tyrosine phosphorylation) of mitogen-activated cytoplasmic kinases, signaling enzymes involved in cell growth and proliferation programs ¹. That suggests the Khavinson peptides adjust long-lived cellular programs rather than simply blocking a receptor, although this remains a working model.

Two related findings add context. Chonluten's own sequence, H-Glu-Asp-Gly-OH, has been examined directly in rat stomach tissue under cyclooxygenase-1/-2 blockade ³, but the available record does not establish the direction of effect or a protective role for that motif. And in aged human neurons grown from donor cells, the related tripeptide Glu-Asp-Arg (EDR/Pinealon), not Chonluten, reduced oxidative DNA damage and promoted the growth of neuron branches (dendritogenesis) ⁵.

There is no direct pharmacokinetic study of Chonluten itself. For short unprotected peptides, blood stability is poor: the related octapeptide THF-γ2, which contains the EDG core, survives intact in human blood less than 6 minutes at body temperature, cut apart by aminopeptidase enzymes and a metallo-endopeptidase ². A free tripeptide is expected to clear at least as fast, which is the mechanistic rationale for injectable, intranasal, or complexed delivery in practice ².

Everything documented for Chonluten, plus one related-peptide finding included for completeness, comes from laboratory studies. The effects below are listed with the model they were observed in.

• Lower inflammatory cytokine output: in LPS-challenged human THP-1 monocytes and macrophages, Chonluten suppressed production of TNF and IL-6, the major pro-inflammatory signaling proteins ¹.
• TNF tolerance: the low-TNF-release pattern matches the documented TNF-tolerance mechanism, an attenuation of inflammatory signaling rather than a block of bacterial sensing ¹.
• Reduced endothelial adhesion: peptide-treated immune cells adhered less to LPS-activated blood-vessel lining, which would blunt inflammatory cell recruitment into tissue ¹.
• Kinase signaling adjustment: all five Khavinson peptides tested increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases, evidence of regulation of proliferative signaling programs ¹.
• Neuronal protection in aged cells (EDR/Pinealon, a different peptide): the related tripeptide Glu-Asp-Arg (EDR/Pinealon), not Chonluten, reduced oxidative DNA damage and promoted dendritogenesis in neurons derived from elderly donor fibroblasts ⁵.
• Mucosal motif studied: Chonluten's own sequence, H-Glu-Asp-Gly-OH, was examined in rat gastric mucosa under COX-1/-2 blockade ³; the direction of effect is not established in the available record.

Strength of evidence is the key caveat. All direct findings are in vitro, meaning in cells in a dish. There are no human randomized trials, no case series, and no controlled clinical data for Chonluten. The research base is dominated by one affiliated investigator network, and the 2022 anti-inflammatory findings have not been independently replicated ¹. Community reports describe easier breathing, better mucus clearance, and faster cold and flu recovery around the second week of a course, with perceived benefit lasting 2 to 6 months, but these reports are low-reliability evidence.

No dose-finding study, clinical trial, or pharmacokinetic study exists for Chonluten, so the schedules below are community and practitioner derived ¹. The timeline card shows the standard subcutaneous course.

The standard injectable protocol is 5 to 20 mcg subcutaneously once daily for 10 days, with an extended 20-day course used for persistent respiratory or immune complaints. Courses are repeated every 4 to 6 months, typically 2 to 3 times per year. Community practice treats this as a flat dose across adult body weights, consistent with the bioregulator model of gene-expression modulation; no weight-based dosing has been validated ¹.

Route choices reflect an open question in the evidence. Short acidic peptides face rapid enzymatic breakdown in blood: the related octapeptide THF-γ2 survives intact less than 6 minutes at body temperature ². Subcutaneous delivery provides gradual depot absorption and is the default route. Oral capsule forms (100 to 200 mcg, once or twice daily for 10 to 30 days) exist from commercial suppliers, but intact tripeptide survival through the gut is uncertain and no validated oral dose exists. Intranasal peptide-complex forms (10 to 20 mcg) are also used.

Timing: morning administration is conventional, on the rationale that immune-modulatory peptides track daytime immune activity, and injectable dosing is meal-independent. For oral forms, community protocols administer on an empty stomach 20 to 30 minutes before food to minimize proteolytic competition. No circadian, meal, or exercise interaction data exist.

Onset and duration: the in vitro effects appear within hours to days of exposure ¹. Community reports attribute first noticeable changes in breathing comfort and mucus clearance to the second week of a course, with maximal effect at the end of the course and in the weeks after. Because the documented action is a reprogramming of the monocyte inflammatory response (TNF tolerance) rather than an acute agonist effect, benefit is expected to outlast the peptide's presence in the body ¹.

Chonluten is supplied as a lyophilized (freeze-dried) powder ¹. The default diluent is bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative; sterile water is acceptable only for single-day use. Add the diluent slowly down the inside wall of the vial and swirl gently. Do not shake: shear forces and foaming can damage peptide chains.

Storage before reconstitution is simple. Unopened vials keep longest at -20°C (one to two years) or at 2-8°C for weeks to months, kept dry and protected from light. Once reconstituted, the solution belongs in the refrigerator at 2-8°C and should not be frozen; freeze-thaw cycles speed peptide breakdown. With bacteriostatic water, standard practice is to discard reconstituted solution after about 28 days refrigerated. With sterile water, the working window is 24 to 72 hours. Avoid heat, extreme pH, and repeated punctures of the vial stopper, and do not leave reconstituted vials at room temperature for more than 4 to 8 hours.

The stability concern is real, not theoretical. Short linear peptides are rapidly degraded by enzymes in biological fluids; the related octapeptide THF-γ2 survives intact in human blood less than 6 minutes ². Properly reconstituted Chonluten retains its anti-inflammatory activity in cell culture, confirming that the peptide remains functional when handled correctly ¹. The interactive calculator in this section handles the dilution arithmetic for any vial size and target dose, so the math does not have to be worked out by hand.

There are no human drug-interaction or pharmacokinetic studies for Chonluten. Everything below combines one documented in vitro mechanism with mechanistic reasoning and practitioner consensus, and severity ratings reflect plausibility rather than observed events ¹.

Drug classes of note:

• TNF inhibitors (infliximab, adalimumab, etanercept): Chonluten reduces LPS-driven TNF release, so the combination stacks two forms of TNF suppression. Theoretical, moderate; infection monitoring matters.
• IL-6 receptor antagonists (tocilizumab, sarilumab): dual suppression of IL-6, and CRP readings may be further dampened, confounding inflammatory monitoring.
• JAK inhibitors (tofacitinib, baricitinib): these block the signaling path that IL-6 uses, so combined with reduced IL-6 release this is a double hit on one pathway. In autoimmune inflammatory disease (e.g., rheumatoid arthritis, inflammatory bowel disease, psoriasis), suppressing TNF and IL-6 may mask disease flares and alter the markers used to guide disease-modifying therapy; do not substitute Chonluten for prescribed immunomodulators, and inform the prescribing clinician about its use.
• Corticosteroids: shared anti-inflammatory direction but low concern; inhaled steroids for asthma or COPD carry no known interaction.
• Vaccines: theoretical concern that monocyte TNF tolerance could blunt vaccine response quality; practitioner consensus is to separate dosing by about 2 weeks.
• Antibiotics during acute bacterial infection: TNF is protective early in infection, so holding Chonluten during an acute febrile infection is the consensus position.

Supplement interactions run in both directions. Anti-inflammatory supplements such as fish oil, curcumin, resveratrol, quercetin, NAC, vitamin C, glutathione, and vitamin D3 are additive rather than antagonistic; stacking several adds no obvious benefit. In the other direction, immune stimulators such as beta-glucan, echinacea, and astragalus enhance macrophage TNF output, functionally opposing Chonluten's TNF-tolerance induction ¹, and are best avoided when immune stimulation is the goal.

Peptide combinations are covered in the stacking section. Within the Khavinson set, all five tested peptides acted in the same anti-inflammatory direction in THP-1 cells ¹, so multi-peptide courses are mechanistically compatible.

Chonluten is used in time-limited courses, not continuously, and the structure comes from the Khavinson bioregulator tradition rather than from measured human pharmacology. Typical patterns:

• Standard conservative: a 20 to 30 day course once daily, then 4 to 6 months off, 2 to 3 courses per year, for maintenance and recurrent respiratory inflammation
• Intensive classic: 10 days once daily, then at least 3 weeks off, 2 to 4 courses per year, for post-infectious bronchopulmonary recovery
• Chronic maintenance: rolling 10 days on and 20 days off for persistent low-grade airway inflammation

The rationale is programmatic rather than pharmacological. Chonluten induces TNF tolerance in monocytes, an attenuation of inflammatory responsiveness that should persist after the peptide clears ¹. The wider peptide family shows durable transcriptional reprogramming: related bioregulators produced lasting remodeling of tightly packed chromatin in lymphocytes from 75- to 88-year-old donors ⁶. And since short peptides survive only minutes in blood ², sustained benefit cannot come from maintained plasma levels anyway; continuous exposure offers no demonstrated advantage.

No tolerance, tachyphylaxis, or dependence data exist for Chonluten. The cycle structure is convention, driven by injection burden, cost, and the use of off-periods to assess effect durability. Signs that a break is appropriate include no further benefit after 3 to 4 weeks, a diminishing subjective response across consecutive courses, cumulative injection-site irritation (site rotation helps), any recurrent minor infections during prolonged use, or a complete course with zero effect on the target indication.

Chonluten is rarely discussed alone in practice; the Khavinson tradition uses multi-peptide courses, and the in vitro data support that habit. All five Khavinson peptides tested in THP-1 cells (Chonluten, Epitalon, Vilon, Thymogen, Thymalin) acted in the same direction: suppressing TNF and IL-6 and reducing immune-cell adhesion to activated endothelium ¹. They behave as cooperating inducers of TNF tolerance, so co-administration is mechanistically compatible.

Combinations with other families:

• BPC-157 and TB-500 (thymosin beta-4 fragment): complementary mechanisms. These peptides support tissue repair and matrix remodeling, while Chonluten suppresses inflammatory cytokines; community protocols commonly combine them for lung and gut mucosal repair. No conflict is identified.
• Thymosin alpha-1: this peptide enhances T-cell and innate immune responses, which is functionally the opposite of Chonluten's TNF suppression ¹. Stacking is theoretically counterproductive when immune stimulation is the goal.
• Growth hormone secretagogues (ipamorelin, sermorelin, CJC-1295): no shared pathway and no expected interaction.
• Anti-inflammatory supplements (fish oil, curcumin): additive cytokine suppression; safe but redundant.

The same caveat applies to every stack: no clinical study has tested combinations involving Chonluten, and the compatibility statements above follow from mechanisms, not from human evidence.

Chonluten is not an approved medicine anywhere. In the United States it holds no FDA approval: no new drug application, no biologic license application, and no publicly documented investigational new drug application. The evidence base is preclinical only ¹.

• Controlled substance status: Chonluten is unscheduled. It is not listed on the US Drug Enforcement Administration's controlled substance schedules and has no scheduled-analogue status.
• Compounding status: Chonluten appears in no USP-NF monograph and no FDA 503A bulk-drug list, so compounding pharmacies lack a legal basis to prepare it. Injectable supply circulates through unofficial channels labeled as research chemicals, cosmetics, or dietary ingredients, and the FDA's 2023 to 2025 enforcement posture treats such products as unapproved new drugs. No Chonluten-specific warning letter is on record. Because tripeptide names and sequences are easily confused (EDG vs EDR) and supply runs through unofficial channels, request a third-party certificate of analysis (COA) with mass-spectrometry or HPLC identity confirmation before use.
• Russia: the compound's scientific and commercial origin. Khavinson Peptides are marketed there in a peptide bioregulator or parapharmaceutical category with no Western drug equivalent, available over the counter.
• EU and UK: no central marketing authorization; unlicensed in the UK, with personal importation carrying customs seizure risk.
• Australia: not on the Australian Register of Therapeutic Goods and unscheduled; the Special Access Scheme or Personal Importation Scheme nominally applies.

Sports status is quiet. Chonluten is not named on the WADA Prohibited List, and its documented activity is cytokine modulation ¹ rather than growth-factor or anabolic signaling. No athlete sanctions involving Chonluten are on record.

There is no human safety dataset for Chonluten: no dedicated safety trial, no dose-tolerability study, and no adverse-event registry. The profile below is built from in vitro mechanistic data, class-level short-peptide data, and community reports ¹.

What the laboratory data show is reassuring in direction. The dominant cellular effect, suppression of TNF and IL-6 release with reduced immune-cell adhesion to activated endothelium ¹, is anti-inflammatory rather than cytotoxic, with no adverse signals reported. Related short tripeptides (EDR/Pinealon and KED), which are distinct from Chonluten, produced no adverse effect on mitochondrial activity, lysosomal activity, or the senescence marker p16 in aged neuron models, and EDR reduced oxidative DNA damage ⁵. No class-level toxicity signal has been identified.

Community-reported effects at typical doses are limited and mild:

• Injection-site reactions: transient redness, stinging, or itching that resolves within hours
• First-day symptoms: mild fatigue or headache in the first 1 to 3 days of a cycle, resolving with continued use
• Blunted fever response during infections, consistent with the TNF-tolerance mechanism ¹
• Nonspecific gastrointestinal upset, with uncertain attribution

Theoretical concerns follow directly from the mechanism. Prolonged continuous use could in principle blunt TNF-dependent host defense against mycobacterial and fungal infections, though no cases are documented. The increased kinase phosphorylation seen in immune cells ¹ is a growth-signaling effect that warrants caution in active malignancy, again with no human data in either direction. No absolute contraindications are established. Relative cautions include active systemic infection, concurrent immunosuppressive or biologic therapy, vaccination within about 2 weeks of a course, pregnancy and breastfeeding (zero data), and pediatric use outside specialist supervision.

Monitoring is practitioner consensus rather than validated medicine: a baseline CBC with differential, CRP, and a chemistry panel, with repeat CBC and CRP every 8 to 12 weeks during long or repeated cycles. No routine TNF or IL-6 measurement is validated for monitoring this peptide.